Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002, a Novel Small Molecule for the Treatment of Antipsychotic-Induced Weight Gain
/PRNewswire/ -- Response Pharmaceuticals, Inc. today announced the successful completion of its Phase 1B clinical trial for the company's lead drug candidate,...
Source: prnewswire.com